Management


Grace E. Colón, Ph.D.
Chairman, President & CEO and Co-Founder
Dr. Colón has over 20 years experience in biopharma, genomics, health care and industrial biotechnology, both in strategic and operational roles with leading public and private companies and as a management consultant at McKinsey.  Her executive roles have spanned a broad range of functions, including corporate development/alliance management, commercial strategy and R&D.  

In addition to her role at Pyranose, Dr. Colón is President and CEO of InCarda Therapeutics, an early
 stage drug delivery company pioneering a novel approach of treating acute cardiovascular diseases/conditions by the inhalation route.  Dr. Colon is also also a biotechnology partner at New Science Ventures.  Most recently she was a corporate Senior Vice President and President of Industrial Products Division at Intrexon Corporation, where she established a new division focused on applying Intrexon’s synthetic biology platform to industrial applications including renewable chemicals, biofuels, biomaterials, specialty proteins and enzymes.  Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials in all therapeutic areas. At Gilead she also created and led both the Alliance Management and Commercial Strategic Planning groups.  Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she was responsible for strategic planning, business intelligence, and project management. She also served as Acting COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Prior to Affymetrix, Dr. Colón was a consultant with McKinsey & Co., where she served clients in health care, biotech, high tech and venture capital.

Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of NIH training grants and conducted doctoral and post-doctoral research on metabolic engineering of industrial amino acid production. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.




Thomas G. Warner, Ph.D.
Chief Scientific Officer, Co-Founder and Director


Dr. Warner is a chemist, glycobiologist and enzymologist with over 30 years experience in the biotechnology industry.  In his most recent position at Intrexon, he served as Director of Analytical Development/Senior Research Fellow, where he established the protein analytics group and played a key role in the strategy and organization of the Protein Production Division.  Prior to this he was Research and Development Leader for glycobiology products at Prozyme where he assisted in the corporate acquisition of Glyko, Inc. (formerly Oxford Glycosystems). He developed several novel analytical tools that are used globally for therapeutic protein characterization.

Dr. Warner began his career in biotechnology at Genentech in the Protein Analytics Group, where, over a 10 year period, he was involved in the development of several key protein products including tissue plasminogen activator factor, thrombopoietin (TPO), Rituxin, Lenercept and DNAse.   He served as team leader of the company-wide glycobiology effort from 1996 to 1998. His laboratory and research interests focused on metabolic engineering of mammalian expression host cells through the control of deleterious gene expression by antisense RNA and gene targeting.

Dr. Warner has over 50 publications and related patents, including several review articles, many dealing with metabolic engineering and optimization of glycosylation of recombinant proteins.  He has held academic appointments as Associate Professor at the University of Tennesee Medical School, Memphis and the University of California, San Diego.  He has served as a grant reviewer for the National Institutes of Health and the National Science Foundation.  He is also a reviewer for several prominent journals and has served on the editorial board of the journal Glycobiology. He received his Ph.D. in chemistry from the University of California, San Diego, and a B.S. in chemistry from the University of Texas, El Paso.